Two more firms get nod for Favipiravir

Two more pharma companies — Zenara of Hyderabad and Mumbai-headquartered BDR — have received the Drugs Controller General of India’s (DCGI) approval to manufacture Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of COVID-19.

Formulations maker Zenara Pharma said it would be selling the product under the brand name Favizen. The tablets are being manufactured at its USFDA-approved facility in Hyderabad. The company is expected to announce the price of the product shortly. BDR Pharmaceuticals said it had received DCGI approval to manufacture Favipiravir to treat mild to moderate patient with COVID-19 symptoms under the brand name BDFAVI. BDFAVI tablets will be priced at Rs. 63 each, sources said.

Recommended for you